miRNA regulation, antitumor activity, and molecular modeling by Naproxen-1,2,4-triazole compound in human Breast cancer

In this study, a new 1,2,4-triazole ring that has a 2-fluorophenyl ring was synthesized using (S)-Naproxen as the starting molecule. The target compound was characterized using spectroscopic methods such as FT-IR, 1H-NMR, 13C-NMR, and HR-MS. In molecular modeling studies, compound (4a) was used to control for the Bcl-2 apoptotic marker. The main aim was to show that the MDA-MB-231 cell line developed growth inhibition in a dose-dependent manner after compound treatment. The results showed that compound (4a) inhibited the motility of MDA-MB-231 cells. Compound (4a) at 75, 150, and 300 µM concentrations significantly reduced the viability of MDA-MB-231 cells compared to the control group. IC50 value of the compound (4a) for 48 h was 57.6 µM. In our study, for the first time, miR-133a-5p was significantly up-regulated in MDA-MB-231 breast cancer cells treated with compound (4a) at different concentrations compared to the control group. As such, miR-133a-5p could play an essential role in tumorigenesis by targeting Bcl-2 in MDA-MB-231 and may be a biomarker for therapeutic targets in breast cancer treatment.